ESMO Immuno-Oncology Congress 2018: Scientific Articles & Press Releases

Interested in what happened during the ESMO Immuno-Oncology Congress 2018?

Read all our news here

Date Title Topic
15 Dec 2018 Data from the OAK Trial Show Fast Progression Is Not More Common with Atezolizumab Lung and other thoracic tumours - Cancer Immunology and Immunotherapy
15 Dec 2018 Pembrolizumab Improves Long-term Overall Survival over Docetaxel in Advanced NSCLC Lung and other thoracic tumours - Cancer Immunology and Immunotherapy
15 Dec 2018 Neoadjuvant Ipilimumab plus Nivolumab Demonstrates Promising Overall Survival and Relapse-free Survival in Stage III Melanoma Cancer Immunology and Immunotherapy
15 Dec 2018 Proton Pump Inhibitor Therapy Negatively Impacts the Efficacy of Nivolumab Plus Ipilimumab Combination Treatment in Melanoma Melanoma and other skin tumours - Cancer Immunology and Immunotherapy
13 Dec 2018 Second-Line Nivolumab Is Not Superior to Chemotherapy in SCLC Lung and other thoracic tumours - Cancer Immunology and Immunotherapy
13 Dec 2018 First Line Immunotherapy Combination Fails to Improve Overall Survival in Lung Cancer [ESMO Press Release] Lung and other thoracic tumours - Cancer Immunology and Immunotherapy
11 Dec 2018 ESMO Immuno-Oncology Congress Showcases New Technologies Set to Improve Cancer Treatment [ESMO Press Release] Cancer Immunology and Immunotherapy